PixarBio Corporation, The Developers Of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President Of External Affairs

CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation inventors of NeuroRelease, a 14-day non-opioid, non-addictive, post-surgical pain treatment with expected FDA approval in 2018, announced today that Glenn Reiser has been appointed Vice President, External Affairs. Glenn joined PixarBio from Pacira Pharmaceuticals in August of 2015.

As a seasoned communicator, Glenn has more than 15 years of experience in the biopharmaceutical sector with expertise in pain treatment. He has led in roles as Investor Relations, Business Development, Marketing, commercial product launches, product development programs, and external communications.

Glenn will continue to report to Frank Reynolds, the company’s founder and Chief Executive Officer. In his new role Glenn will lead Investor & Public Relations, and Medical & Scientific Affairs. He is responsible for managing the overall external reputation of PixarBio Corporation through key activities such as media relations, local community engagement and branding. Glenn will develop, manage and deliver globally integrated external communications plans that demonstrate PixarBio’s revolutionary science and innovative culture. Responsibilities align to the company’s growing leadership infrastructure, and in maintaining momentum toward commercialization of NeuroRelease™, PixarBio’s Morphine Strength Non-Addictive Pain Treatment™, with expected FDA approvals in 2018.

“Glenn has overachieved in his role at PixarBio. We recruited Glenn from Pacira Pharmaceuticals to support product roll-out, but we have tapped into his unlocked talents and we are expanding his role in our company. He brings industry experience and business acumen to every meeting and keeps everyone on their toes. We will succeed in short order and Glenn is a key fit for our team’s success," said PixarBio CEO Frank Reynolds.

About PixarBio Corporation
Cofounded by Frank M. Reynolds, MIT’s Dr. Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For more information visit www.pixarbio.com.